Global Aptamers Market 2022-2026 The analyst has been monitoring the aptamers market and it is poised to grow by $ 1.31 bn during 2022-2026, progressing at a CAGR of 27.70% during the forecast period. Our report on the aptamers market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing incidence of cancer boosts demand for novel diagnostics and rising number of clinical trials to develop aptamer-based therapeutics. In addition, the increasing incidence of cancer boosts demand for novel diagnostics is anticipated to boost the growth of the market as well. The aptamers market analysis includes the application segment and geographic landscape.
The aptamers market is segmented as below: By Application • Therapeutics development • Research and development • Diagnostic • Others
By Geographical Landscape • North America • Europe • Asia • ROW
This study identifies the rising awareness of the advantages of aptamers over antibodiesas one of the prime reasons driving the aptamers market growth during the next few years.
The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on aptamers market covers the following areas: • Aptamers market sizing • Aptamers market forecast • Aptamers market industry analysis
This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading aptamers market vendors that include Aptagen LLC, Aptamer Group Ltd., Aptamer Sciences Inc, APTATARGETS SL, Base Pair Biotechnologies Inc., Kaneka Corp., Maravai LifeSciences Holdings Inc., NeoVentures Biotechnology Inc, SomaLogic Inc, and Vivonics Inc. Also, the aptamers market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Our reports have been used by over 10K customers, including:
Orphan Drugs Market by Disease Type (Oncological Diseases, Metabolic Diseases, Hematologic & Immunologic Diseases, Infectious Diseases, Neurologic Diseases, and Other Rare Diseases): Global Opportunity Analysis and Industry Forecast, 2021–2030 The global orphan drugs market was valued at $1,40,000.0 million in...
Global Oncology Precision Medicine Market to Reach $1,28,891.6 Million by 2031 Market Report Coverage - Oncology Precision Medicine Market Segmentation • Ecosystem - Precision Therapeutics, Applied Sciences, Digital Health and Information Technology, Precision Diagnostics • Application...
175 pages •
By The Business Research Company
• Mar 2022
Major players in the brain tumor drugs market are Pfizer Inc., Shimadzu Corporation, Toshiba Medical Systems, Merck & Co. Inc., AstraZeneca, Carestream Health, Philips Healthcare, Siemens Healthineers, Hitachi Medical Corporation and GE Healthcare. The global brain tumor drugs market is expected to grow from $3.17 billion in 2021 to...
Leiomyosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Leiomyosarcoma - Drugs In Development, 2022, provides an overview of the Leiomyosarcoma (Oncology) pipeline landscape. Leiomyosarcoma...
Fibrosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Fibrosarcoma - Drugs In Development, 2022, provides an overview of the Fibrosarcoma (Oncology) pipeline landscape. Fibrosarcoma...
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) pipeline Target constitutes close to 48 molecules. Out of which...
300 pages •
By The Business Research Company
• Mar 2022
Major companies in the oncology drugs market include F.Hoffmann-La Roche Ltd., Novartis AG, Gilead Sciences Inc., Bayer AG and Takeda Pharmaceticals. The global oncology drugs market is expected to grow from $199.95 billion in 2021 to $223.21 billion in 2022 at a compound annual growth rate (CAGR) of 11.6%. The growth is mainly due...
Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) - Serine/threonine-protein...
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary According to the recently published report ’Protein Kinase C Theta Type - Drugs In Development, 2022’; Protein Kinase...
Toll Like Receptor 8 (CD288 or TLR8) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary According to the recently published report ’Toll Like Receptor 8 - Drugs In Development, 2022’; Toll Like Receptor 8 (CD288 or TLR8) pipeline...
Cancer
Pharmaceutical
Therapy
Biopharmaceutical
Drug Development
World
Prescription Drug Sales
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.